Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-0057 in PSMA-positive mCRPC
NCT07310355Phase 2Not yet recruiting
- Sponsor
- StarRay Therapeutics
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Peptides
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu-177 PSMA-0057 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by StarRay Therapeutics. Primary endpoints: Incidence of adverse events [68Ga-PSMA-0057] at 3 days, Incidence of adverse events [177Lu-PSMA-0057] at 2 years and 2 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
lutetium Lu-177 PSMA-0057
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07310355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310355.